Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop
Plain English summary Patients with rare diseases often help to develop new treatments for their conditions. But once developed, those treatments are sometimes priced too high for many patients to access them. We became aware that this is a problem in the course of a social science research project...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-09-01
|
| Series: | Research Involvement and Engagement |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40900-017-0065-z |
| _version_ | 1831724373583593472 |
|---|---|
| author | Koichi Mikami Steve Sturdy |
| author_facet | Koichi Mikami Steve Sturdy |
| author_sort | Koichi Mikami |
| collection | DOAJ |
| description | Plain English summary Patients with rare diseases often help to develop new treatments for their conditions. But once developed, those treatments are sometimes priced too high for many patients to access them. We became aware that this is a problem in the course of a social science research project that examines the place of rare diseases in health policy. We therefore organized a two-day workshop to try and understand why this problem occurs and what might be done about it. The people who participated in our workshop were: representatives of rare disease patient organizations, experts in matters of drug regulation and assessment of new health technologies, consultants involved with companies producing treatments for rare diseases, and social scientists researching related issues. The main conclusions to emerge from the discussions were as follows: Problems of access to treatments for rare diseases are not just due to high prices; procedures for regulating, assessing and delivering new treatments also need to be better organized. Patients and patient organizations have much to contribute to this process. However, their resources are often very limited. Consequently, more needs to be done to help them use those resources as effectively as possible. In particular, regulators and healthcare providers need to ensure that their procedures are clear and efficiently managed, so as not to waste patient organizations’ time and money. Clearer guidance is needed on what patient organizations can do to provide evidence of the effectiveness of new drugs. Insights gained in tackling rare diseases might also be applicable to common disorders. Finally, the consequences of Brexit for UK policies on rare diseases urgently need to be assessed. Abstract Since the enactment of orphan drug legislation in the USA, Europe and several other countries, an increasing number of treatments for rare diseases have been developed and many of them been approved for marketing. However, such treatments tend to be priced very high, and access to effective treatments remains a major challenge for patients with rare diseases – despite active involvement of patients and their support organizations in various stages of basic and applied research and commercial development. In order to allow patients to benefit from treatments proved effective for their diseases, we need to better understand why this challenge persists, and what steps might be taken to address it. To that end, we organized a policy-engagement workshop, bringing together individuals and organizations with direct experience of trying to secure access to a treatment for a rare disease along with individuals with relevant expertise in regulatory and commissioning processes for new medicines. With additional input from social scientists who offered different perspectives on the value of patient involvement, the workshop aimed to initiate a dialogue among the participants about how to address the challenge in a sustainable manner. Discussions at the workshop stressed that active involvement of patients is as valuable in the regulatory and commissioning processes as in the research and development of new medicines. However, it also highlighted certain risks and costs associated with such involvement. These include the costs of adjusting to abrupt changes in regulatory and commissioning processes, and the risk of being perceived as too close to commercial interests. To optimize use of scarce resources and ensure continuing active involvement, such risks and costs need to be better managed. Participants also noted that, owing to advances in genomic technologies, common diseases are also becoming divided into rare sub-categories, which are equally eligible for orphan drug designation. Consequently, involvement of wider patient communities beyond rare disease communities will be critical for continuing discussions about patients’ involvement in regulatory and commissioning processes, and to consider how patients and their support organizations can best work with other stakeholders – including companies, regulators and policymakers – to ensure access to effective medicines. |
| first_indexed | 2024-12-21T04:20:50Z |
| format | Article |
| id | doaj.art-318c53ab7425484f96d1d50131f82bba |
| institution | Directory Open Access Journal |
| issn | 2056-7529 |
| language | English |
| last_indexed | 2024-12-21T04:20:50Z |
| publishDate | 2017-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Research Involvement and Engagement |
| spelling | doaj.art-318c53ab7425484f96d1d50131f82bba2022-12-21T19:16:11ZengBMCResearch Involvement and Engagement2056-75292017-09-013111310.1186/s40900-017-0065-zPatient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshopKoichi Mikami0Steve Sturdy1Science Interpreter Training Program, KOMEX, University of TokyoScience, Technology and Innovation Studies, SSPS, University of EdinburghPlain English summary Patients with rare diseases often help to develop new treatments for their conditions. But once developed, those treatments are sometimes priced too high for many patients to access them. We became aware that this is a problem in the course of a social science research project that examines the place of rare diseases in health policy. We therefore organized a two-day workshop to try and understand why this problem occurs and what might be done about it. The people who participated in our workshop were: representatives of rare disease patient organizations, experts in matters of drug regulation and assessment of new health technologies, consultants involved with companies producing treatments for rare diseases, and social scientists researching related issues. The main conclusions to emerge from the discussions were as follows: Problems of access to treatments for rare diseases are not just due to high prices; procedures for regulating, assessing and delivering new treatments also need to be better organized. Patients and patient organizations have much to contribute to this process. However, their resources are often very limited. Consequently, more needs to be done to help them use those resources as effectively as possible. In particular, regulators and healthcare providers need to ensure that their procedures are clear and efficiently managed, so as not to waste patient organizations’ time and money. Clearer guidance is needed on what patient organizations can do to provide evidence of the effectiveness of new drugs. Insights gained in tackling rare diseases might also be applicable to common disorders. Finally, the consequences of Brexit for UK policies on rare diseases urgently need to be assessed. Abstract Since the enactment of orphan drug legislation in the USA, Europe and several other countries, an increasing number of treatments for rare diseases have been developed and many of them been approved for marketing. However, such treatments tend to be priced very high, and access to effective treatments remains a major challenge for patients with rare diseases – despite active involvement of patients and their support organizations in various stages of basic and applied research and commercial development. In order to allow patients to benefit from treatments proved effective for their diseases, we need to better understand why this challenge persists, and what steps might be taken to address it. To that end, we organized a policy-engagement workshop, bringing together individuals and organizations with direct experience of trying to secure access to a treatment for a rare disease along with individuals with relevant expertise in regulatory and commissioning processes for new medicines. With additional input from social scientists who offered different perspectives on the value of patient involvement, the workshop aimed to initiate a dialogue among the participants about how to address the challenge in a sustainable manner. Discussions at the workshop stressed that active involvement of patients is as valuable in the regulatory and commissioning processes as in the research and development of new medicines. However, it also highlighted certain risks and costs associated with such involvement. These include the costs of adjusting to abrupt changes in regulatory and commissioning processes, and the risk of being perceived as too close to commercial interests. To optimize use of scarce resources and ensure continuing active involvement, such risks and costs need to be better managed. Participants also noted that, owing to advances in genomic technologies, common diseases are also becoming divided into rare sub-categories, which are equally eligible for orphan drug designation. Consequently, involvement of wider patient communities beyond rare disease communities will be critical for continuing discussions about patients’ involvement in regulatory and commissioning processes, and to consider how patients and their support organizations can best work with other stakeholders – including companies, regulators and policymakers – to ensure access to effective medicines.http://link.springer.com/article/10.1186/s40900-017-0065-zRare diseasesOrphan drugsPatient organizationsPartnershipDrug development |
| spellingShingle | Koichi Mikami Steve Sturdy Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop Research Involvement and Engagement Rare diseases Orphan drugs Patient organizations Partnership Drug development |
| title | Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop |
| title_full | Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop |
| title_fullStr | Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop |
| title_full_unstemmed | Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop |
| title_short | Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop |
| title_sort | patient organization involvement and the challenge of securing access to treatments for rare diseases report of a policy engagement workshop |
| topic | Rare diseases Orphan drugs Patient organizations Partnership Drug development |
| url | http://link.springer.com/article/10.1186/s40900-017-0065-z |
| work_keys_str_mv | AT koichimikami patientorganizationinvolvementandthechallengeofsecuringaccesstotreatmentsforrarediseasesreportofapolicyengagementworkshop AT stevesturdy patientorganizationinvolvementandthechallengeofsecuringaccesstotreatmentsforrarediseasesreportofapolicyengagementworkshop |